Madrigal Pharmaceuticals Inc (MDGL)
329.24
+12.15
(+3.83%)
USD |
NASDAQ |
Nov 21, 16:00
329.00
-0.24
(-0.07%)
After-Hours: 20:00
Madrigal Pharmaceuticals Enterprise Value: 6.299B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 6.299B |
| November 20, 2024 | 6.034B |
| November 19, 2024 | 5.971B |
| November 18, 2024 | 5.738B |
| November 15, 2024 | 5.413B |
| November 14, 2024 | 5.720B |
| November 13, 2024 | 5.992B |
| November 12, 2024 | 6.513B |
| November 11, 2024 | 6.527B |
| November 08, 2024 | 6.767B |
| November 07, 2024 | 6.858B |
| November 06, 2024 | 6.495B |
| November 05, 2024 | 6.482B |
| November 04, 2024 | 6.345B |
| November 01, 2024 | 6.089B |
| October 31, 2024 | 4.775B |
| October 30, 2024 | 3.828B |
| October 29, 2024 | 3.869B |
| October 28, 2024 | 3.851B |
| October 25, 2024 | 3.712B |
| October 24, 2024 | 3.545B |
| October 23, 2024 | 3.534B |
| October 22, 2024 | 3.558B |
| October 21, 2024 | 3.674B |
| October 18, 2024 | 3.795B |
| Date | Value |
|---|---|
| October 17, 2024 | 3.708B |
| October 16, 2024 | 3.820B |
| October 15, 2024 | 3.832B |
| October 14, 2024 | 3.816B |
| October 11, 2024 | 3.788B |
| October 10, 2024 | 3.710B |
| October 09, 2024 | 3.717B |
| October 08, 2024 | 3.845B |
| October 07, 2024 | 3.803B |
| October 04, 2024 | 3.663B |
| October 03, 2024 | 3.623B |
| October 02, 2024 | 3.679B |
| October 01, 2024 | 3.683B |
| September 30, 2024 | 3.746B |
| September 27, 2024 | 3.671B |
| September 26, 2024 | 3.703B |
| September 25, 2024 | 3.753B |
| September 24, 2024 | 3.902B |
| September 23, 2024 | 3.960B |
| September 20, 2024 | 4.129B |
| September 19, 2024 | 4.319B |
| September 18, 2024 | 4.121B |
| September 17, 2024 | 4.126B |
| September 16, 2024 | 4.126B |
| September 13, 2024 | 4.309B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
519.25M
Minimum
Apr 03 2020
6.858B
Maximum
Nov 07 2024
2.362B
Average
1.492B
Median
Oct 01 2020
Enterprise Value Benchmarks
| Corcept Therapeutics Inc | 5.479B |
| ADMA Biologics Inc | 5.050B |
| 89bio Inc | 597.11M |
| Sarepta Therapeutics Inc | 10.58B |
| Matinas BioPharma Holdings Inc | -7.845M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -106.96M |
| Revenue (Quarterly) | 62.18M |
| Total Expenses (Quarterly) | 178.48M |
| EPS Diluted (Quarterly) | -4.92 |
| Gross Profit Margin (Quarterly) | 96.54% |
| Profit Margin (Quarterly) | -172.0% |
| Earnings Yield | -7.63% |
| Normalized Earnings Yield | -7.630 |